CA Patent

CA3153099A1 — Methods of treating epileptic patients with fenfluramine

Assigned to Zogenix International Ltd · Expires 2021-03-25 · 5y expired

What this patent protects

The present disclosure provides methods of treating and/or preventing symptoms of epilepsy or epileptic encephalopathy where fenfluramine or a pharmaceutically acceptable salt thereof is or has been administered to a patient or population of patients. The present disclosure encom…

USPTO Abstract

The present disclosure provides methods of treating and/or preventing symptoms of epilepsy or epileptic encephalopathy where fenfluramine or a pharmaceutically acceptable salt thereof is or has been administered to a patient or population of patients. The present disclosure encompasses a recognition of contraindication of fenfluramine and certain serotonin receptor agonists, particularly a CNS penetrant serotonin receptor antagonist. The present disclosure provides methods where said patients being administered fenfluramine have been warned against co-administration of certain serotonin receptor antagonists, are not co-administered a serotonin receptor antagonist, and/or in which co-administration of a serotonin-receptor antagonist is discontinued.

Drugs covered by this patent

Patent Metadata

Patent number
CA3153099A1
Jurisdiction
CA
Classification
Expires
2021-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Zogenix International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.